25 March, 2009 -- Pronova BioPharma ASA today announces that it and its U.S. marketing partner GlaxoSmithKline Inc. have received a Paragraph IV Notice Letter dated March 20 2009 from Apotex Inc. advising that Apotex has submitted an Abbreviated New Drug Application to the US FDA for approval to market a generic version of Lovaza(TM).
The details can be read here.
No comments:
Post a Comment